Dorchester Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $1.09M | Hold |
19,340
| – | – | 0.22% | 71 |
|
|
2024
Q3 | $1M | Buy |
19,340
+6,108
| +46% | +$287K | 0.18% | 75 |
|
|
2024
Q2 | $550K | Sell |
13,232
-1,098
| -8% | -$49.1K | 0.11% | 90 |
|
|
2024
Q1 | $777K | Buy |
14,330
+855
| +6% | +$43.6K | 0.14% | 87 |
|
|
2023
Q4 | $691K | Sell |
13,475
-119
| -0.9% | -$6.25K | 0.13% | 84 |
|
|
2023
Q3 | $789K | Sell |
13,594
-800
| -6% | -$49K | 0.16% | 83 |
|
|
2023
Q2 | $920K | Hold |
14,394
| – | – | 0.19% | 70 |
|
|
2023
Q1 | $998K | Buy |
14,394
+2,800
| +24% | +$197K | 0.21% | 69 |
|
|
2022
Q4 | $834K | Sell |
11,594
-3,050
| -21% | -$230K | 0.2% | 71 |
|
|
2022
Q3 | $1.04M | Hold |
14,644
| – | – | 0.23% | 68 |
|
|
2022
Q2 | $1.13M | Sell |
14,644
-550
| -4% | -$41.9K | 0.22% | 69 |
|
|
2022
Q1 | $1.39M | Sell |
15,194
-75
| -0.5% | -$5.04K | 0.22% | 63 |
|
|
2021
Q4 | $952K | Sell |
15,269
-800
| -5% | -$46.9K | 0.19% | 67 |
|
|
2021
Q3 | $951K | Sell |
16,069
-1,199
| -7% | -$79K | 0.23% | 63 |
|
|
2021
Q2 | $1.15M | Sell |
17,268
-3,725
| -18% | -$243K | 0.26% | 59 |
|
|
2021
Q1 | $1.32M | Buy |
20,993
+797
| +4% | +$49.6K | 0.33% | 54 |
|
|
2020
Q4 | $1.25M | Buy |
20,196
+1,403
| +7% | +$86.3K | 0.33% | 54 |
|
|
2020
Q3 | $1.13M | Sell |
18,793
-112
| -0.6% | -$6.74K | 0.35% | 54 |
|
|
2020
Q2 | $1.11M | Buy |
18,905
+1,528
| +9% | +$91.4K | 0.35% | 56 |
|
|
2020
Q1 | $969K | Sell |
17,377
-148
| -0.8% | -$9.05K | 0.36% | 51 |
|
|
2019
Q4 | $1.13M | Sell |
17,525
-1,878
| -10% | -$108K | 0.31% | 55 |
|
|
2019
Q3 | $984K | Sell |
19,403
-997
| -5% | -$46.9K | 0.29% | 54 |
|
|
2019
Q2 | $925K | Hold |
20,400
| – | – | 0.27% | 56 |
|
|
2019
Q1 | $973K | Hold |
20,400
| – | – | 0.3% | 53 |
|
|
2018
Q4 | $1.06M | Hold |
20,400
| – | – | 0.37% | 48 |
|
|
2018
Q3 | $1.27M | Sell |
20,400
-700
| -3% | -$41.5K | 0.39% | 45 |
|
|
2018
Q2 | $1.17M | Hold |
21,100
| – | – | 0.38% | 47 |
|
|
2018
Q1 | $1.33M | Sell |
21,100
-1,300
| -6% | -$83.6K | 0.45% | 45 |
|
|
2017
Q4 | $1.37M | Sell |
22,400
-249
| -1% | -$15.6K | 0.43% | 48 |
|
|
2017
Q3 | $1.44M | Sell |
22,649
-375
| -2% | -$21.9K | 0.46% | 48 |
|
|
2017
Q2 | $1.28M | Buy |
23,024
+524
| +2% | +$28.5K | 0.44% | 48 |
|
|
2017
Q1 | $1.22M | Hold |
22,500
| – | – | 0.43% | 49 |
|
|
2016
Q4 | $1.31M | Sell |
22,500
-700
| -3% | -$38.3K | 0.48% | 48 |
|
|
2016
Q3 | $1.25M | Sell |
23,200
-300
| -1% | -$19.3K | 0.47% | 48 |
|
|
2016
Q2 | $1.73M | Sell |
23,500
-250
| -1% | -$17.7K | 0.64% | 44 |
|
|
2016
Q1 | $1.52M | Hold |
23,750
| – | – | 0.57% | 44 |
|
|
2015
Q4 | $1.63M | Sell |
23,750
-500
| -2% | -$33K | 0.68% | 42 |
|
|
2015
Q3 | $1.92M | Sell |
24,250
-2,200
| -8% | -$140K | 0.71% | 41 |
|
|
2015
Q2 | $2.2M | Buy |
+26,450
| New | +$1.74M | 0.72% | 43 |
|
Other funds holding BMY
Dorchester Wealth Management's BMY Position: Q4 2024 in Review
Dorchester Wealth Management held its Bristol-Myers Squibb (BMY) position steady in Q4 2024 at 19,340 shares worth $1.09M. The position accounts for 0.22% of the portfolio, ranked #71.
Dorchester Wealth Management first reported a position in BMY in Q2 2015 and has held it in 39 quarters since. The position peaked at $2.2M in Q2 2015. 2,486 funds tracked by Wall St. Rank hold BMY as of Q4 2024.
- Dorchester Wealth Management held 19,340 shares of Bristol-Myers Squibb worth $1.09M as of Q4 2024.
- Dorchester Wealth Management left its Bristol-Myers Squibb share count unchanged in Q4 2024.
- Bristol-Myers Squibb made up 0.22% of Dorchester Wealth Management's portfolio in Q4 2024, its #71 holding.
- Dorchester Wealth Management first reported a position in Bristol-Myers Squibb in Q2 2015 and has held it in 39 quarters since.
- Dorchester Wealth Management's Bristol-Myers Squibb position peaked at $2.2M in Q2 2015.
- 2,486 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2024.
Based on Dorchester Wealth Management's 13F filing for Q4 2024, filed 4 Feb 2025.